General MedicationsOPHTHALMICStandard
RYZUMVI
PHENTOLAMINE MESYLATE
Standard Dose
EQ 0.75% BASE
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview RYZUMVI is listed in Drugs@FDA under application 217064 (NDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient PHENTOLAMINE MESYLATE Form and strength SOLUTION;OPHTHALMIC - EQ 0.75% BASE Sponsor FAMYGEN LIFE SCI Submission history Latest submission status date: 2023-11-28 00:00:00.
Structured Monograph
Clinical summary
Approval overview RYZUMVI is listed in Drugs@FDA under application 217064 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient PHENTOLAMINE MESYLATE Form and strength SOLUTION;OPHTHALMIC - EQ 0.75% BASE Sponsor FAMYGEN LIFE SCI Submission history Latest submission status date: 2023-11-28 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.